Human Genome Epidemiology Literature Finder
Records 1 - 13 (of 13 Records) |
Query Trace: Vomiting and EGFR[original query] |
---|
A phase II trial of erlotinib in combination with gemcitabine and capecitabine in previously untreated metastatic/recurrent pancreatic cancer: combined analysis with translational research. Investigational new drugs 2012 Jun 30 (3): 1164-74. Oh Do-Youn, Lee Keun Wook, Lee Kyung-Hee, Sohn Chang-Hak, Park Young Suk, Zang Dae Young, Ryoo Hun-Mo, Song Hong-Suk, Kim Jin-Soo, Kang Hye-Jin, Kim Bong-Seog, Bang Yung-J |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2011 1 17 (5): 1131-9. Jänne Pasi A, Boss David S, Camidge D Ross, Britten Carolyn D, Engelman Jeffrey A, Garon Edward B, Guo Feng, Wong Steven, Liang Jane, Letrent Stephen, Millham Robert, Taylor Ian, Eckhardt S Gail, Schellens Jan H |
Comparative study analyzing survival and safety of bevacizumab/carboplatin/paclitaxel and cisplatin/pemetrexed in chemotherapy-naïve patients with advanced non-squamous bronchogenic carcinoma not harboring EGFR mutation. OncoTargets and therapy 2013 6 803-9. Kader Yasser Abdel, Le Chevalier Thierry, El-Nahas Tamer, Sakr A |
Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis. Targeted oncology 2015 Jun . Guetz Gaetan Des, Landre Thierry, Uzzan Bernard, Chouahnia Kader, Nicolas Patrick, Morere Jean-Franço |
Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Annals of oncology : official journal of the European Society for Medical Oncology 2015 1 26 (5): 998-1005. Wong A L, Soo R A, Tan D S, Lee S C, Lim J S, Marban P C, Kong L R, Lee Y J, Wang L Z, Thuya W L, Soong R, Yee M Q, Chin T M, Cordero M T, Asuncion B R, Pang B, Pervaiz S, Hirpara J L, Sinha A, Xu W W, Yuasa M, Tsunoda T, Motoyama M, Yamauchi T, Goh B |
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet. Oncology 2015 Feb 16 (2): 141-51. Yang James Chih-Hsin, Wu Yi-Long, Schuler Martin, Sebastian Martin, Popat Sanjay, Yamamoto Nobuyuki, Zhou Caicun, Hu Cheng-Ping, O'Byrne Kenneth, Feng Jifeng, Lu Shun, Huang Yunchao, Geater Sarayut L, Lee Kye Young, Tsai Chun-Ming, Gorbunova Vera, Hirsh Vera, Bennouna Jaafar, Orlov Sergey, Mok Tony, Boyer Michael, Su Wu-Chou, Lee Ki Hyeong, Kato Terufumi, Massey Dan, Shahidi Mehdi, Zazulina Victoria, Sequist Lecia |
First-line icotinib versus cisplatin/pemetrexed plus pemetrexed maintenance therapy for patients with advanced EGFR mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study. Annals of oncology : official journal of the European Society for Medical Oncology 2017 9 28 (10): 2443-2450. Shi Y K, Wang L, Han B H, Li W, Yu P, Liu Y P, Ding C M, Song X, Ma Z Y, Ren X L, Feng J F, Zhang H L, Chen G Y, Han X H, Wu N, Yao C, Song Y, Zhang S C, Song W, Liu X Q, Zhao S J, Lin Y C, Ye X Q, Li K, Shu Y Q, Ding L M, Tan F L, Sun |
Gefitinib Versus Adjuvant Chemotherapy in Patients With Stage II-IIIA Non-Small-Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study. Clinical lung cancer 2018 11 19 (6): 484-492. Xie Hounai, Wang Hui, Xu Lin, Li Meng, Peng Yue, Cai Xianyun, Feng Zhen, Ren Wangang, Peng Zhongm |
The Effect of Next-Generation TKI in Non-Small Cell Lung Cancer after Failure of First-Line Treatment: a Meta-Analysis. Pathology oncology research : POR 2019 6 26 (2): 1137-1143. Zhang Lei, Ren Hong-Wei, Wu Qi-Long, Wu Yan-Juan, Song Xia |
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer discovery 2021 2 11 (7): 1688-1699. Riely Gregory J, Neal Joel W, Camidge D Ross, Spira Alexander I, Piotrowska Zofia, Costa Daniel B, Tsao Anne S, Patel Jyoti D, Gadgeel Shirish M, Bazhenova Lyudmila, Zhu Viola W, West Howard L, Mekhail Tarek, Gentzler Ryan D, Nguyen Danny, Vincent Sylvie, Zhang Steven, Lin Jianchang, Bunn Veronica, Jin Shu, Li Shuanglian, Jänne Pasi |
FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. Clinical cancer research : an official journal of the American Association for Cancer Research 2022 9 29 (3): 508-512. Duke Elizabeth S, Stapleford Liza, Drezner Nicole, Amatya Anup K, Mishra-Kalyani Pallavi S, Shen Yuan-Li, Maxfield Kimberly, Zirkelbach Jeanne Fourie, Bi Youwei, Liu Jiang, Zhang Xinyuan, Wang Hezhen, Yang Yuching, Zheng Nan, Reece Kelie, Wearne Emily, Glen Jacqueline J, Ojofeitimi Idara, Scepura Barbara, Nair Abhilasha, Bikkavilli Rama Kamesh, Ghosh Soma, Philip Reena, Pazdur Richard, Beaver Julia A, Singh Harpreet, Donoghue Mart |
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. ESMO open 2022 6 7 (3): 100506. Boccaccino A, Borelli B, Intini R, Antista M, Bensi M, Rossini D, Passardi A, Tamberi S, Giampieri R, Antonuzzo L, Noto L, Roviello G, Zichi C, Salati M, Puccini A, Noto C, Parisi A, Rihawi K, Persano M, Crespi V, Libertini M, Giordano M, Moretto R, Lonardi S, Cremolini |
Predictive Value of EGFR Mutation Status for First-Line Tyrosine Kinase Inhibitor Treatment in Patients with Advanced Lung Cancer. Alternative therapies in health and medicine 2023 12 . Youqin Xie, Jinliang Chen, Wen Zhu, Zhihui Ye, Xuedong |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 06, 2024
- Content source: